ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
- Conditions
- Transitional Cell Cancer of Renal Pelvis and Ureter
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 100
- Registration Number
- NCT04620239
- Locations
- 🇫🇷
HCL Hopital Edouard Herriot, Lyon, France
🇺🇸University of California - Irvine Medical Center, Irvine, California, United States
🇺🇸Medical University of South Carolina (MUSC), Charleston, South Carolina, United States
Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer
- First Posted Date
- 2020-01-13
- Last Posted Date
- 2020-11-13
- Lead Sponsor
- Steba Biotech S.A.
- Registration Number
- NCT04225299
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
European Randomised Study of TOOKAD® Soluble for Prostate Cancer vs Active Surveillance. Post Study Follow-up
- Conditions
- Cancer of the Prostate
- Interventions
- Other: no intervention (post study follow up)
- First Posted Date
- 2019-07-12
- Last Posted Date
- 2021-03-22
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 374
- Registration Number
- NCT04017325
- Locations
- 🇫🇮
Department of Urology-Tampere University Hospital-, Tampere, Finland
🇫🇷Site Médipole, Cabestany, France
🇫🇷CHRU Hopital Jean Minjoz, Besançon, France
Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate Cancer
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 23
- Registration Number
- NCT03849365
- Locations
- 🇫🇷
Centre Hospitalier Universitaire (CHU), Angers, France
Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer.
- Conditions
- Localized Prostate Cancer
- Interventions
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 50
- Registration Number
- NCT03315754
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2016-04-19
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 81
- Registration Number
- NCT01875393
- Locations
- 🇲🇽
Hospital General Tlahuac, Mexico DF, Mexico
🇵🇦Pan-American Medical Research Institute (PAMRI) then moved to Consultario del Dr Rodriguez, Panama city, Panama
🇵🇪Hospital Nacional Cayetano Heredia, San Martin de Porres, Peru
Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.
- First Posted Date
- 2011-03-09
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 413
- Registration Number
- NCT01310894
- Locations
- 🇳🇱
Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Polikliniek Urologie-Catharina Ziekenhuis, Eindhoven, Netherlands
🇫🇷Clinique Urologique Nantes, Saint Herblain, France
Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD
- Conditions
- Macular DegenerationChoroidal Neovascularization
- Interventions
- Drug: STAKEL
- First Posted Date
- 2009-12-01
- Last Posted Date
- 2018-09-17
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 10
- Registration Number
- NCT01021956
- Locations
- 🇺🇸
Johns Hopkins,Wilmer Eye Institute, Baltimore, Maryland, United States
🇺🇸Palmetto Retina Center, West Columbia, South Carolina, United States
🇫🇷Hotel Dieu de Paris Hospital, Paris, France
Study Using WST11 in Patients With Localized Prostate Cancer
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2015-04-28
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 86
- Registration Number
- NCT00975429
- Locations
- 🇫🇷
Hôpital Claude Huriez, Lille, France
🇫🇷Centre Hospitalier Universitaire (CHU), Angers, France
🇫🇷Institut Mutualiste Montsouris(IMM), Paris, France
Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2016-04-18
- Lead Sponsor
- Steba Biotech S.A.
- Target Recruit Count
- 8
- Registration Number
- NCT00975039
- Locations
- 🇫🇷
Clinique de l'Alma, Paris, France